NC
SPRY icon

nVerses Capital’s ARS Pharmaceuticals SPRY Stock Holding History

nVerses Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
+12,845
New +$110K 0.16% 242
2024
Q4 		– Sell
-2,100
Closed -$30.4K – 766
2024
Q3 		$30.4K Buy
+2,100
New +$25K 0.01% 741

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

nVerses Capital's SPRY Position: Q2 2026 in Review

nVerses Capital opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 12,845 shares worth $103K. The stake represents 0.16% of the portfolio and ranks #242 among its holdings. This is a return to the name: nVerses Capital previously reported a position in SPRY as recently as Q3 2024.

nVerses Capital first reported a position in SPRY in Q3 2024 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • nVerses Capital held 12,845 shares of ARS Pharmaceuticals worth $103K as of Q2 2026.
  • ARS Pharmaceuticals was a new nVerses Capital position in Q2 2026.
  • ARS Pharmaceuticals made up 0.16% of nVerses Capital's portfolio in Q2 2026, its #242 holding.
  • nVerses Capital first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.